1. Home
  2. GHI vs ANIX Comparison

GHI vs ANIX Comparison

Compare GHI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

GHI

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

HOLD

Current Price

$6.31

Market Cap

121.3M

Sector

Finance

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.82

Market Cap

114.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GHI
ANIX
Founded
1998
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
121.3M
114.0M
IPO Year
1998
2013

Fundamental Metrics

Financial Performance
Metric
GHI
ANIX
Price
$6.31
$2.82
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$10.50
$8.67
AVG Volume (30 Days)
58.8K
269.1K
Earning Date
05-12-2026
05-27-2026
Dividend Yield
22.93%
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
$85,389,766.00
$210,000.00
Revenue This Year
$273.95
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.71
$2.32
52 Week High
$10.94
$5.46

Technical Indicators

Market Signals
Indicator
GHI
ANIX
Relative Strength Index (RSI) 51.13 31.69
Support Level $6.01 $2.73
Resistance Level $6.76 $3.09
Average True Range (ATR) 0.20 0.21
MACD -0.04 -0.08
Stochastic Oscillator 25.68 2.51

Price Performance

Historical Comparison
GHI
ANIX

About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: